Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 36, 2002 - Issue 2
Submit an article Journal homepage
88
Views
26
CrossRef citations to date
0
Altmetric
Research Article

A Comparative Randomized and Placebo-controlled Short-term Trial of Aspirin and Dipyridamole for Overt Type-2 Diabetic Nephropathy

P. Khajehdehi Divisions of Nephrology and Endocrinology, Department of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
,
J. Roozbeh Divisions of Nephrology and Endocrinology, Department of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
&
H. Mostafavi Divisions of Nephrology and Endocrinology, Department of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Pages 145-148 | Published online: 09 Jul 2009

  • American Diabetes Association. Diabetic nephropathy. Diabetic Care 1998; 21 (Suppl): S50-3.
  • Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol 1998; 9: 2157-69.
  • Ritz E. Nephropathy in type 2 diabetes. J Intern Med 1999;245:111-26.
  • Deferrari G, Repetto M, Calvi C, Ciabattoni M, Rossi C, Robaudo C. Diabetic nephropathy: from micro- to macroalbuminuria. Nephrol Dial Transplant 1998; 13 (Suppl 8): 11-15.
  • Mogensen CE. Preventing end-stage renal disease. Diabetic Med 1998; 15 (Suppl 4): S51-6.
  • Jerums G. Differences in renal outcomes with ACE inhibitors in type 1 and type 2 diabetic patients: possible explanations. Miner Electrolyte Metab 1998; 24: 423-37.
  • Winchester J. Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis 1996; 28 (Suppl 1): S20-3.
  • Moel DI, Sa? rstein RL, McEvoy RC, Hsueh W. Effect of aspirin on experimental diabetic nephropathy. J Lab Clin Med 1987; 110: 300-7.
  • De Cosmo S, Earle K, Morocutti A, Walker J, Ruggenenti P, Remuzzi G, Viberti GC. Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulin-dependent)diabeticpatients:inhibitionby acetylsalicilic acid infusion. Diabetologia 1993; 36: 622-7.
  • De la Cruz JP, Moreno A, Munoz M, Garcia-Campos JM, Sanchez de la Cuesta F. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J Pharmacol Exp Ther1997; 280:454-9.
  • Duclos-J. Is it justi? able to use antiplatelet drugs as a universal protection in patients with chronic glomerular damage? Rev Med Chil 1993; 121: 286-91.
  • Giustina A, Perini P, Desenzani P, Bossoni S, Inniello P, Milani M, Davi G,Romanelli G. Long-term treatment with the dual antithrombaxane agent picotamide decreasesmicroalbuminuriainnormotensivetype2 diabetic patients. Diabetes 1998; 47: 423-30.
  • Hopper AH, Tindall H, Davies A. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy. Nephrol Dial Transplant 1989; 4: 140-3.
  • Donadio JV, Ilstrup DM, Holley KE, Romero JC. Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study. Mayo Clin Proc 1988; 63: 3-15.
  • Pugh JA, Medina R, Ramirez M. Comparison of the course to end-stage renal disease of type 1 (insulin-dependent) and type 2 (non-insulin-dependent ) diabetic nephropathy. Diabetologia 1993; 36: 1094-8.
  • Orisio S. Gene polymorphism of the renin-angiotensin system and progression of diabetic nephropathy. J Nephrol 1999; 12: 9-17.
  • Kuramoto N, Iizuka T, Ito H, Yagui K, Omura M, Nozaki O, Nishikawa T, Tsuchida H, Makino H, Saito Y, Kanatsuka A. Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am J Kidney Dis 1999; 33: 276-81.
  • UK Prospective Diabetes Study Group. Ef? cacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317(7160): 713-20.
  • American Diabetes Association. Aspirin therapy in diabetes. Diabetic Care 1998; 21 (Suppl 1): S45-6.
  • Hillis GS, Duthie LA, MacLeod AM. Dipyridamole inhibits human mesengial cell proliferation. Nephron 1998;78:172-8.
  • Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular ? ltration rate, and end stage renal failure in chronic renal disease in patients without diabetes. Br Med J 1998; 316: 504-9.
  • Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int 1998; 53: 1209-16.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.